Drug profile · INN
denosumab-mobz
BONCRESA
denosumab-mobz (BONCRESA) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — denosumab-mobz
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
denosumab-mobz (BONCRESA) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is denosumab-mobz?
denosumab-mobz (BONCRESA) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for denosumab-mobz?
BONCRESA is a marketed brand name for denosumab-mobz. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of denosumab-mobz?
denosumab-mobz has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.